CNF 2024

Drug Profile

CNF 2024

Alternative Names: BIIB-021; CNF2024

Latest Information Update: 15 Sep 2014

Price : $50

At a glance

  • Originator Biogen Idec
  • Class Antineoplastics; Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Breast cancer; Gastrointestinal stromal tumours; Solid tumours

Most Recent Events

  • 01 Apr 2011 Biogen Idec completes a phase I trial in Breast cancer (combination therapy) in USA (NCT00412412)
  • 04 Feb 2011 CNF 2024 is available for licensing as of 04 Feb 2011. www.biogenidec.com
  • 06 Jan 2011 Biogen Idec completes a phase I trial (NCT00618735) in Solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top